A Multi-institutional Analysis of Acute Toxicity After Neoadjuvant Chemoradiation Using Photons or Protons in Trimodality Esophageal Cancer Patients
Michael D. Chuong(Baptist Hospital of Miami), Steven H. Lin(The University of Texas MD Anderson Cancer Center), Christopher L. Hallemeier(Mayo Clinic in Arizona), Ritsuko Komaki(The University of Texas MD Anderson Cancer Center), Neha Bhooshan(University of Maryland, Baltimore), Pamela K. Allen(The University of Texas MD Anderson Cancer Center), Michael G. Haddock(Mayo Clinic in Arizona), Zhongxing Liao(Thoracic Surgery Foundation), Kenneth W. Merrell(Mayo Clinic), M. Suntharalingam(University of Maryland, Baltimore), Minesh P. Mehta(Columbia University)
International Journal of Radiation Oncology*Biology*Physics
October 17, 2015
Cited by 7
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k